Los Angeles - 
(NewMediaWire) - June 16, 2021 - The Schall Law Firm, a national shareholder rights litigation firm,
announces that it is investigating claims on behalf of investors of Ocugen,
Inc. (“Ocugen” or “the Company”) (NASDAQ: OCGN) for violations of the securities laws.
The investigation focuses on whether the Company
issued false and/or misleading statements and/or failed to disclose information
pertinent to investors. Ocugen announced on May 26, 2021, that it planned to
submit an Emergency Use Authorization (“EUA”) application for COVAXIN, a
COVID-19 vaccine, to the FDA in June 2021. The Company announced on June 10,
2021, that it “will no longer pursue an Emergency Use Authorization (EUA) for
COVAXIN,” choosing instead to “pursue submission of a biologics license
application (BLA) for its COVID-19 vaccine candidate, COVAXIN.” The Company’s
Chairman and CEO stated, “Although we were close to finalizing our EUA
application for submission, we received a recommendation from the FDA to pursue
a BLA path,” and that “this will extend our timelines.” Based on this news,
shares of Ocugen fell by more than 24% in intraday trading on the same day.
If you are a shareholder who
suffered a loss, click here to
participate.
We also encourage you to contact
Brian Schall of the Schall Law Firm, 2049
Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also
reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.
The class in this case has not
yet been certified, and until certification occurs, you are not represented by
an attorney. If you choose to take no action, you can remain an absent class
member.
The Schall Law Firm represents
investors around the world and specializes in securities class action lawsuits
and shareholder rights litigation.
This press release may be
considered Attorney Advertising in some jurisdictions under the applicable law
and rules of ethics.
CONTACT:
The Schall
Law Firm
Brian Schall, Esq.
310-301-3335
